Evidence map›Paper›PMID 38563132›Full record

ArticleACS infectious diseases2024

Effectiveness of Two New Endochin-like Quinolones, ELQ-596 and ELQ-650, in Experimental Mouse Models of Human Babesiosis.

Pratap Vydyam, Meenal Chand, Sovitj Pou, Rolf W Winter, Katherine M Liebman, Aaron Nilsen, J Stone Doggett, Michael K Riscoe, Choukri Ben Mamoun

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Antimicrobial agents and chemotherapy · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Pratap VydyamORCID 0000-0003-4944-6006
Meenal Chand
Sovitj PouExperimental Chemotherapy Lab, VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Rolf W WinterExperimental Chemotherapy Lab, VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Katherine M LiebmanExperimental Chemotherapy Lab, VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Aaron NilsenExperimental Chemotherapy Lab, VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.ORCID 0000-0002-3827-8222
J Stone DoggettExperimental Chemotherapy Lab, VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.ORCID 0000-0002-6098-1520
Michael K RiscoeExperimental Chemotherapy Lab, VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.ORCID 0000-0002-1343-5279
Choukri Ben Mamoun
Oregon Health & Science University · USPortland VA Medical Center · USYale University · US

Funding

Optimizing ELQs for Treatment and Prevention of MalariaR01AI100569 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Michael Kevin RISCOE · 2014 to 2026
$8.0M
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria TreatmentR01AI138139 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BEN MAMOUN, CHOUKRI, LE ROCH, KARINE GAELLE · 2018 to 2022
$3.6M
Development of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQsR01AI141412 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI RISCOE, MICHAEL KEVIN · 2019 to 2022
$3.2M
Development of endochin-like quinolones for babesiosis therapyR01AI123321 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2017 to 2020
$2.7M
Antigen Discovery and Vaccine Development for Human Babesia ParasitesR01AI152220 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2020 to 2024
$2.1M
An antigen-detection assay to diagnose Babesia microti infectionR44AI136118 · NIAID · L2 DIAGNOSTICS, LLC · PI LEDIZET, MICHEL · 2020 to 2022
$2.1M
Next Generation ELQs for Treatment and Once-Monthly Protection Against MalariaR01AI182513 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Michael Kevin RISCOE, AKHIL B VAIDYA · 2025 to 2026
$1.2M
An antigen-detection assay to diagnose Babesia microti infectionR43AI136118 · NIAID · L2 DIAGNOSTICS, LLC · PI LEDIZET, MICHEL · 2018 to 2018
$300k
BLR&D Research Career Scientist Renewal Award ApplicationIK6BX004857 · VA · PORTLAND VA MEDICAL CENTER · PI Michael Kevin RISCOE · 2020 to 2026
–
Novel Therapeutic Strategies for ELQ-422, a preclinical Toxoplasmosis Drug CandidateI01BX004522 · VA · PORTLAND VA MEDICAL CENTER · PI Joseph Stone Doggett · 2019 to 2026
–
Pharmachin Optimization and TestingI01BX003312 · VA · PORTLAND VA MEDICAL CENTER · PI RISCOE, MICHAEL KEVIN · 2016 to 2025
–
Optimizing Pharmachins for Treatment and Prevention of Drug Resistant MalariaI01BX001421 · VA · PORTLAND VA MEDICAL CENTER · PI RISCOE, MICHAEL KEVIN · 2012 to 2015
–
BLRD VA I01 BX001421BLRD VA I01 BX003312BLRD VA I01 BX004522BLRD VA IK6 BX004857NIAID NIH HHS R01 AI100569NIAID NIH HHS R01 AI123321NIAID NIH HHS R01 AI138139NIAID NIH HHS R01 AI141412NIAID NIH HHS R01 AI152220NIAID NIH HHS R01 AI182513NIAID NIH HHS R43 AI136118NIAID NIH HHS R44 AI136118
6 · The paper itself

Abstract

Endochin-like quinolones (ELQs) define a class of small molecule antimicrobials that target the mitochondrial electron transport chain of various human parasites by inhibiting their cytochrome bc

Indexed as

BabesiosisQuinolonesAnimalsAtovaquoneHumansMiceAtovaquoneQuinolonesBabesiaB. duncaniB. microtiELQ-596endochin-like quinoloneshuman babesiosisparasite

Identifiers

PMID38563132
PMCPMC11127568
OpenAlexW4393427705

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.